Simply put, the mission of Perseid Therapeutics is to discover and develop protein
drugs that improve human health. Perseid seeks to create products that deliver significant
patient benefit both by improving upon known mechanisms and by discovering novel
therapeutic modalities. Our initial focus has been on patients suffering from disorders
treatable by immune suppressive therapy. We also discover and develop novel protein
pharmaceuticals using the proprietary MolecularBreedingTM directed molecular
MolecularBreedingTM Directed Molecular Evolution Platform
Perseid Therapeutics uses a number of proprietary technologies that enable rapid
identification of protein therapeutic drug candidates with optimal biophysical properties.
Our integrated technologies combine advances in molecular biology, immunology and
protein evolution to generate novel immunomodulatory protein therapeutics.
Our discovery strategies include the use of a proprietary directed molecular evolution
platform which utilizes a number of proprietary DNA shuffling formats. The MolecularBreedingTM
directed molecular evolution platform harnesses the natural power of evolution in
vitro to generate proteins having desired properties, such as enhanced target
binding affinity and selectivity. Such properties may provide clinical benefit in
terms of improved efficacy, safety, and/or patient convenience.
The MAXY-4 program has created next-generation CTLA4-Ig molecules for the treatment
of rheumatoid arthritis, transplant rejection and other diseases. By binding to
human B7 (CD80/CD86) ligands with high avidity, CTLA4-Ig fusion proteins inhibit
B7-mediated co-stimulation of T cells via the CD28 receptor, thereby decreasing
activation of T cells and thus decreasing immune system activation. Perseid staff
used the MolecularBreedingTM directed molecular evolution platform to
generate novel CTLA4-Ig proteins with significantly higher binding affinity and
altered selectivity to human B7 ligands.
Maxy-4 and Rheumatoid Arthritis
The worldwide market for rheumatoid arthritis (RA), a key opportunity for MAXY-4,
has grown to over $10 billion. The increasing global incidence of severe RA and
the emergence of new therapies with improved clinical benefit are predicted to sustain
market expansion in this disease area.
A significant segment of the RA population continues to be refractory to current
biological DMARDs, and clinical benefit (as measured by ACR50 score) is estimated
at less than 50% at six months post therapy. Hence, significant opportunity remains
available for the introduction of new biologic therapies, such as MAXY-4, that aim
to provide a differentiated benefit over existing therapies.
Maxy-4 and Transplant Rejection
The worldwide market opportunity for solid organ transplant rejection was over $3
billion in 2007. Although standard of care agents (tacrolimus, MMF, steroids) provide
high short term survival rates, longer-term survival rates (>5 years) remain poor.
Maxy-4 compounds aim to address this significant unmet need by providing increased
safety and efficacy.
Perseid has multiple pre-clinical discovery programs that aim to deliver significant
patient benefit by either improving upon known protein therapies or providing new
therapeutic modalities. Perseid uses its proprietary MolecularBreedingTM
directed molecular evolution platform and other technologies, such as bi-functional
proteins, to discover the most appropriate drug format to address a particular unmet
To learn more about how Perseid uses its proprietary technologies to discover, research
and develop novel protein pharmaceutical products, please visit the
Perseid Therapeutics Web site